Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Japanese drug company Eisai will expand its Alzheimer’s disease research through a collaboration between Boston University School of Medicine and the drug firm’s Andover innovative Medicines (AiM) Institute. The partnership is focused on the relationship between genetic variants related to Alzheimer’s and microglia, immune cells found in the brain. AiM Institute’s immuno-dementia research is part of a growing trend of searching for immune system- and inflammation-related targets to treat Alzheimer’s.
This article has been sent to the following recipient: